BRAF mutations in an Italian cohort of thyroid cancers

被引:160
作者
Fugazzola, L
Mannavola, D
Cirello, V
Vannucchi, G
Muzza, M
Vicentini, L
Beck-Peccoz, P
机构
[1] Univ Milan, Inst Endocrine Sci, Milan, Italy
[2] Osped Maggiore, IRCCS, Endocrine Surg Unit, Milan, Italy
关键词
D O I
10.1111/j.1365-2265.2004.02089.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE Recently, a somatic point mutation of the BRAF gene (V599E) has been identified as the most common genetic event in papillary thyroid carcinoma (PTC) with a variable frequency (about 25-70%) in different series from USA, Japan, Portugal and Ukraine. DESIGN In the present study, the genetic analysis of BRAF in an Italian cohort of 65 thyroid tumours with corresponding normal tissues and 21 thyroid benign disorders is reported. METHODS For BRAF analysis, the somatic DNA was PCR amplified by means of specific intronic primers and PCR products were directly sequenced. Statistical analyses were obtained by means of Fisher's exact test. RESULTS All mutations detected involved a T > A transversion at 1796 (V599E) and were heterozygous. Overall, BRAF(V599E) mutation was found in 18/56 (32.1%) PTCs. According to the histological type of the tumour, the mutation was present in 38.3% of cases of conventional PTC (18/47), in 0/6 follicular variant of PTC, in 0/3 oncocytic variant of PTC. No BRAF mutations were detected either in five follicular carcinomas, or in four poorly differentiated or undifferentiated cancers or in benign thyroid disorders. No statistically significant correlation of BRAF mutation with patient age and gender, with multicentricity of the tumour, with the lymphocytic infiltration of the tissue, with the stage and with the recurrence rate, was found. BRAF(V599E) tended to be associated, although not significantly, with a greater volume and extension of the tumour and with lymph-nodal metastases at surgery. CONCLUSIONS In conclusion, the present study on the first Italian series of thyroid cancers shows a frequency of 38.3% of BRAF(V599E) in the classical variant of PTC, confirming the key role of this mutation in promoting tumourigenesis.
引用
收藏
页码:239 / 243
页数:5
相关论文
共 21 条
[1]  
American Joint Committee on Cancer - Thyroid, 2002, AJCC CANC STAG HDB, P89
[2]  
Bongarzone I, 1998, CLIN CANCER RES, V4, P223
[3]   BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility:: The Italian melanoma intergroup study [J].
Casula, M ;
Colombino, M ;
Satta, MP ;
Cossu, A ;
Ascierto, PA ;
Bianchi-Scarrà, G ;
Castiglia, D ;
Budroni, M ;
Rozzo, C ;
Manca, A ;
Lissia, A ;
Carboni, A ;
Petretto, E ;
Satriano, SMR ;
Botti, G ;
Mantelli, M ;
Ghiorzo, P ;
Stratton, IR ;
Tanda, F ;
Palmieri, G .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (02) :286-292
[4]   BRAF mutation in papillary thyroid carcinoma [J].
Cohen, J ;
Xing, MZ ;
Mambo, E ;
Guo, ZM ;
Wu, GG ;
Trink, B ;
Beller, U ;
Westra, WH ;
Ladenson, PW ;
Sidransky, D .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (08) :625-627
[5]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[6]   BRAF mutations in papillary carcinomas of the thyroid [J].
Fukushima, T ;
Suzuki, S ;
Mashiko, M ;
Ohtake, T ;
Endo, Y ;
Takebayashi, Y ;
Sekikawa, K ;
Hagiwara, K ;
Takenoshita, S .
ONCOGENE, 2003, 22 (41) :6455-6457
[7]  
Kimura ET, 2003, CANCER RES, V63, P1454
[8]   BRAF and KRAS mutations in stomach cancer [J].
Lee, SH ;
Lee, JW ;
Soung, YH ;
Kim, HS ;
Park, WS ;
Kim, SY ;
Lee, JH ;
Park, JY ;
Cho, YG ;
Kim, CJ ;
Nam, SW ;
Kim, SH ;
Lee, JY ;
Yoo, NJ .
ONCOGENE, 2003, 22 (44) :6942-6945
[9]   Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers [J].
Namba, H ;
Nakashima, M ;
Hayashi, T ;
Hayashida, N ;
Maeda, S ;
Rogounovitch, TI ;
Ohtsuru, A ;
Saenko, VA ;
Kanematsu, T ;
Yamashita, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (09) :4393-4397
[10]  
Naoki K, 2002, CANCER RES, V62, P7001